- Inflectra(셀트리온/Pfizer)
: 82.5천 Unit(+13.9% MoM), MS 11.8%(+0.6%p)
- Renflexis(삼성바이오/MSD)
: 45.6천 Unit(+16.1% MoM), MS 6.5%(+0.4%p)
2) Rituximab 바이오시밀러 : MS Ruxience > Truxima 역전
- Truxima(셀트리온/TEVA)
: 986.7천 Unit(+7.7% MoM), MS 19.8%(+0.3%p)
- Ruxience(Pfizer)
: 1,031.3천 Unit(+18.3% MoM), MS 20.7%(+2.1%p)
3) Trastuzumab 바이오시밀러 : 처방수량 모두 증가, MS 격차 확대
- Kanjinti(Amgen/Abbvie)
: 1,217.1천 Unit(+21.9% MoM), MS 42.4%(+1.8%p)
: 232.5천 Unit(+19.1% MoM), MS 8.1%(+0.2%p)
- Others(Trazimera+Herzuma)
: 212.1천 Unit(+22.0% MoM), MS 7.4%(+1.2%p)
4) Bevacizumab 바이오시밀러 : MS 상승폭 Zirabev > Mvasi
- Mvasi(Amgen/Abbvie)
: 2,113.1 천 Unit(+14.2 % MoM), MS 47.3%(+0.5%p)
: 433.4천 Unit(+27.5% MoM), MS 9.7%(+1.1%p)
작성자: 김지하 메리츠증권 연구원
장태민 기자 chang@fntimes.com